Hearing loss in adults surviving pneumococcal meningitis is associated with otitis and pneumococcal serotype  by Heckenberg, S.G.B. et al.
Hearing loss in adults surviving pneumococcal meningitis is associated
with otitis and pneumococcal serotype
S. G. B. Heckenberg1, M. C. Brouwer1, A. van der Ende2,3, E. F. Hensen4 and D. van de Beek1
1) Departments of Neurology and 2) Medical Microbiology, Centre of Infection and Immunity Amsterdam (CINIMA), 3) the Netherlands Reference
Laboratory for Bacterial Meningitis, Academic Medical Centre and 4) Department of Otolaryngology and Head and Neck Surgery, VU University Medical
Centre, Amsterdam, the Netherlands
Abstract
We assessed the incidence of hearing loss and its relationship with clinical characteristics and pneumococcal serotypes in adults
surviving pneumococcal meningitis. We analysed hearing loss in 531 adults surviving pneumococcal meningitis included in two prospec-
tive nationwide cohort studies performed from April 1998 through to October 2002 and March 2006 through to January 2009. Hearing
loss was evaluated on admission and discharge for all patients. Severe hearing loss was assessed by pure tone average on audiology and
corrected for age, or by the combination of hearing loss on discharge and a score on the Glasgow Outcome Scale below 5, which could
not be explained by other neurological sequelae. A total of 531 episodes of pneumococcal meningitis with non-lethal outcome were
included. Predisposing conditions for pneumococcal meningitis were present in the majority of patients (64%), most commonly otitis
(36%). Hearing loss was present at discharge in 116 patients (22%) and was classiﬁed as mild in 53% and severe in 47%. Hearing loss
was related to otitis (odds ratio [OR], 2.58; 95% conﬁdence interval [CI], 1.66–4.02; p < 0.001) and inversely related to serotype 23F
infection (OR, 0.36; 95% CI, 0.13–0.98; p = 0.025), but not with parameters of disease severity or indicators of cerebrospinal ﬂuid
inﬂammation severity. Meningitis due to pneumococcal serotype 3 was associated with the highest rate of hearing loss. Hearing loss fre-
quently complicates pneumococcal meningitis. Risk factors for hearing loss were infection with pneumococcal serotype 23F and otitis,
but not disease severity. Otitis and resulting perilympathic inﬂammation contribute to meningitis-associated hearing loss.
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Background
Bacterial meningitis is a severe and life-threatening infectious
disease [1]. Streptococcus pneumoniae is the most severe
cause of bacterial meningitis and currently accounts for
70% of all cases of community-acquired bacterial meningi-
tis.[2] Hearing loss commonly complicates the clinical course
of pneumococcal meningitis and is an important cause of
disability, with reported rates of 7% to 36% among survivors
of pneumococcal meningitis.[1,3–6]
Few studies have identiﬁed clinical risk factors for menin-
gitis-associated hearing loss.[3–12] The most commonly
described risk factors for hearing loss were age, a low level
of consciousness, infection with S. pneumoniae, and cerebro-
spinal ﬂuid (CSF) and serum parameters of inﬂammation.
[3–12] A recent retrospective cohort study showed that
advanced age, female sex, presence of co-morbidity and
pneumococcal serotype were associated with an increased
risk of hearing loss.[4] The inﬂuence of serotype on hearing
loss has not been described previously and may inﬂuence
vaccination policy and development.
In the current study we assessed the incidence of hearing
loss in two prospective nationwide studies on pneumococcal
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meningitis and studied the role of pneumococcal serotypes
in the development of hearing loss.
Methods
We pooled data from patients with pneumococcal meningitis
from two prospective nationwide cohort studies with similar
design.[3,13] In these studies adults (deﬁned as patients older
than 16 years of age) were included who had bacterial menin-
gitis deﬁned by positive cerebrospinal ﬂuid (CSF) culture, and
were listed in the database of the Netherlands Reference
Laboratory for Bacterial Meningitis from April 1998 through
to October 2002, and from March 2006 to January 2009.
This laboratory receives CSF isolates from approximately
85% of all patients with bacterial meningitis in the Nether-
lands (population, 16.2 million).[3,13] Daily updates were
provided of hospitals where patients with bacterial meningitis
had been admitted in the preceding 2–6 days. Physicians were
informed about the study by telephone. Patients or their legal
representatives received written information concerning the
study and were asked to give written informed consent for
participation. Case record forms were used to collect data.
Patients with negative CSF cultures or hospital-associated
meningitis were excluded. Patients with an altered immune
status due to the use of immunosuppressive drugs or sple-
nectomy, diabetes mellitus or alcoholism were considered
immunocompromised, as were patients infected with HIV.
Outcome was graded according to the Glasgow Outcome
Scale. A score of 1 on this scale indicates death; a score of 2
a vegetative state (the patient is unable to interact with the
environment); a score of 3 severe disability (the patient is
unable to live independently but can follow commands); a
score of 4 moderate disability (the patient is capable of living
independently but unable to return to work or school); and
a score of 5 mild or no disability (the patient is able to
return to work or school). A favourable outcome was
deﬁned as a score of 5, and an unfavourable outcome as a
score of 1–4. The Glasgow Outcome Scale is a well-validated
instrument with good interobserver agreement.[14] At dis-
charge, all surviving patients underwent a neurological exami-
nation performed by a neurologist.
Hearing loss was evaluated on admission, during admission
and on discharge for all patients. Audiological follow-up was
performed at the discretion of the treating physician. Audio-
grams performed within 1 year of admission were retrieved
in patients with a history of hearing loss on admission, during
admission or at discharge. Audiograms were re-evaluated by
an otolaryngologist (EH) and a neurologist (SH). Pure tone
audiometry at 500, 1000, 2000 and 4000 Hz was used to
calculate the pure tone average (PTA). The PTA was cor-
rected for any coexistent conductive hearing loss by subtract-
ing the air-bone gap. Finally, an age- and sex-matched dataset
was used to correct the PTA values.[15] By correcting for
conductive hearing loss, age and sex, we obtained the cor-
rected pure tone average (cPTA). We categorized patients
into four categories: patients with a cPTA of <10 decibels
(dB) uni- or bilaterally (no hearing loss), patients with a cPTA
of 10–30 dB uni- or bilaterally (mild hearing loss), patients
with a cPTA of 31–70 dB uni- or bilaterally (moderate hear-
ing loss) and patients with a cPTA >70dB (severe hearing
loss).[4] We analysed patients with any hearing loss and those
with moderate to severe hearing loss, which was deﬁned as
by cPTA >30 Patients with the combination of hearing loss at
discharge and a score on the Glasgow Outcome Scale below
5, which was not caused by other neurological sequelae, were
also categorized as having moderate to severe hearing loss.
Clinical hearing loss in the case record form was not speciﬁed
as uni- or bilateral hearing loss.
The Mann–Whitney U-test was used to identify differences
between groups with respect to continuous variables, and
dichotomous variables were compared by use of the chi-
squared test. All statistical tests were two-tailed, and a p
value of <0.05 was regarded as signiﬁcant. Analyses were
undertaken with PASW software, version 18 (SPSS, Armonk,
NY, USA). We used logistic regression analysis to assess the
association between potential prognostic factors and the
probability of any or severe hearing loss.
Results
A total of 709 episodes of pneumococcal meningitis in 697
patients were included in the two cohort studies; 352 in
1998–2002 and 357 in 2006–2009. One hundred and sev-
enty-eight episodes were fatal (25%), so 531 episodes of
adult pneumococcal meningitis were available for evaluation
in this study.
Predisposing conditions for pneumococcal meningitis were
present in 342 patients (64%), and consisted of otitis in 195
patients (36%; Table 1). On presentation, classic symptoms
and signs of bacterial meningitis were present in a large pro-
portion of patients. Headache occurred in 87% of episodes,
neck stiffness in 81%, fever in 86%, and a change in mental
status (deﬁned by a Glasgow Coma Scale score below 14) in
81%. In 15% of episodes, the patients were comatose on
admission, and in 9% of episodes, a hemiparesis was present
on presentation. A lumbar puncture was performed in all
patients, and the median white blood cell (WBC) count was
3004 (interquartile range [IQR], 893–8121).
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Hearing loss was noted during 187 of 531 episodes (35%):
on or during admission only in 71 patients, and at discharge
in 116 patients (Table 2). Audiological examination was per-
formed in 82 of 187 patients with hearing loss (44%).
According to our predeﬁned criteria, hearing loss was pres-
ent in 73 audiograms and was classiﬁed as mild in 30 epi-
sodes (37%), moderate in 25 (30%) and severe in 18
episodes (22%). For the other 105 episodes complicated by
hearing loss in which audiology was not performed, hearing
loss was still present on discharge in 43 (41%) of these
patients. In 12 (28%) of these episodes without audiograms,
hearing loss was classiﬁed as severe hearing loss as it caused
unfavourable outcome. Combining the clinical and audiology
data we concluded that any hearing loss was present on dis-
charge in 116 episodes (22%). The degree of hearing loss
was classiﬁed as moderate to severe hearing loss in 55 epi-
sodes (47%). Clinical features of patients with audiological
examination and with clinical hearing loss were similar,
except for diastolic hypotension, which was more common
on presentation in patients receiving audiological follow-up
(17% vs. 2%, p = 0.03). Hearing loss in audiograms was most
pronounced in the highest frequency (4000 Hz).
In a univariate analysis, the presence of otitis on presenta-
tion was associated with hearing loss at discharge (odds ratio
[OR], 2.58; 95% conﬁdence interval [CI], 1.66–4.02;
p < 0.001; Table 2). Of the 195 patients with otitis, 64 devel-
oped hearing loss (33%). The association with otitis was
present in patients with audiologically conﬁrmed hearing loss
(p < 0.001) and in patients with clinical hearing loss
TABLE 1. Baseline characteristics of 531 patients with
pneumococcal meningitis
Characteristic Value
Age (years) 59 (45–68)
Male sex 242/531 (46%)
Duration of symptoms >24 h 251/509 (49%)
Predisposing conditions 342/531 (64%)
Otitis 195/522 (37%)
Sinusitis 90/509 (18%)
Pneumonia 66/523 (13%)
Immunocompromise 111/530 (21%)
Symptoms and signs on admission
Headache 417/479 (87%)
Neck stiffness 420/519 (81%)
Fever 385/447 (86%)
Diastolic blood pressure <60 mmHg 39/523 (7%)
GCS on admission 11 (9–13)
<14 (indicating change in mental status) 428/531 (81%)
<8 (indicating coma) 80/531 (15%)
Focal neurological abnormalities on admission
Hemiparesis 47/498 (9%)
Cranial nerve palsy 66/498 (13%)
Hearing loss 26/454 (6%)
Indices of CSF inﬂammation
White cell count (cells/mm3)a 3004 (893–8121)
CSF protein (g/L)b 3.9 (2.4–5.9)
CSF/blood glucose ratioc 0.04 (0.01–0.24)
CSF pressure (cm H2O)
d 40 (29–50)
Blood tests
ESR, mm/he 42 (22–72)
C-reactive protein, mg/Lf 185 (92–203)
Thrombocyte count, platelets/mm3g 207 (163–262)
Numbers are number/number evaluated or median (interquartile range [IQR]).
GCS, Glasgow coma scale; CSF, cerebrospinal ﬂuid; ESR, erythrocyte sedimenta-
tion rate.
aCSF white cell count was available for 498 episodes.
bCSF protein was available for 492 episodes.
cCSF/blood glucose ratio was available for 486 episodes.
dCSF pressure was available for 172 episodes.
eESR was available for 369 episodes.
fC-reactive protein was available for 389 episodes.
gThrombocyte count was available for 501 episodes.
TABLE 2. Characteristics of 531
patients with pneumococcal men-
ingitis according to occurrence of
hearing loss
Characteristic Any hearing loss No hearing loss p value
No. of episodes 116 415
Age (years) 56 ± 14 57 ± 15 0.49
Male sex 49/116 (42%) 193/415 (47%) 0.41
Duration of symptoms >24 h 53/111 (48%) 198/398 (50%) 0.71
Predisposing conditions
Otitis 64/116 (55%) 131/406 (32%) <0.001
Sinusitis 24/109 (22%) 66/400 (17%) 0.18
Pneumonia 15/114 (13%) 51/409 (12%) 0.84
Immunocompromise 22/116 (19%) 89/414 (21%) 0.55
Symptoms and signs on admission
Headache 96/108 (89%) 321/371 (87%) 0.52
Neck stiffness 91/114 (80%) 329/405 (81%) 0.73
Diastolic blood pressure <60 mmHg 13/115 (11%) 26/408 (6%) 0.08
Hemiparesis 12/104 (12%) 35/394 (9%) 0.41
Score on GCS
<14 (indicating change in mental status) 92/115 (80%) 336/415 (81%) 0.81
<8 (indicating coma) 13/115 (11%) 67/415 (16%) 0.20
Indices of CSF inﬂammation
White cell count (cells/mm3)a 3370 (762–8692) 2933 (902–8000) 0.40
CSF protein (g/L)b 4.1 (2.8–5.8) 3.8 (2.3–5.9) 0.27
CSF/blood glucose ratioc 0.04 (0.00–0.21) 0.05 (0.01–0.24) 0.57
Numbers are number/number evaluated or median (IQR).
GCS, Glasgow coma scale; CSF, cerebrospinal ﬂuid.
aCSF white cell count was available for 498 episodes.
bCSF protein was available for 492 episodes.
cCSF/blood glucose ratio was available for 486 episodes.
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(p = 0.003). Clinical severity, as reﬂected in scores on the
Glasgow Coma Scale, and parameters of CSF inﬂammation,
were not predictive for the development of hearing loss.
Patients with severe hearing loss had lower CSF/blood glu-
cose ratios, as compared with those without severe hearing
loss (ratio of 0.03 [IQR, 0.00–0.08] vs. 0.05 [IQR 0.01–0.25];
p = 0.02), but all other clinical and laboratory characteristics
were similar between groups. In a multivariate analysis with
possible predictors of hearing loss (sinusitis, otitis, diastolic
hypotension and coma on admission), otitis on admission
remained the only predictor of hearing loss (p < 0.001).
Treatment data for otitis were not available for a sufﬁcient
number of patients to assess the inﬂuence of, for example,
mastoidectomy on hearing loss on discharge.
Serotype analysis was performed for 504 of 531 pneumo-
coccal isolates (95%; Table 3). The most common capsular
serotypes were 3, 7F, 23F, 14, 6B and 19F, together account-
ing for 47% of isolates. The coverage of the 7-, 10- and 13-
valent vaccines of these isolates would be 40%, 53% and 68%,
respectively. Compared with the reference serotype 3 (the
most common serotype), the risk of hearing loss was lower
for all other serotypes. Any hearing loss during clinical course
occurred less frequently in patients infected with S. pneumo-
niae serotype 14 (OR, 0.28; 95% CI, 0.09–0.80; p = 0.007)
and serotype 23F (OR, 0.36; 95% CI, 0.13–0.98; p = 0.025),
as compared with serotype 3. Infection with the S. pneumo-
niae serotype 23F was also associated with less hearing loss
at discharge (OR, 0.32; 95% CI, 0.08–1.19; p = 0.05) and
showed a trend towards less severe hearing loss at discharge
(OR, 0.19; 95% CI, 0.01–1.71; p = 0.10), but conﬁdence
intervals were wide because of small numbers. S. pneumoniae
serotype 14 was not related to hearing loss at discharge.
Initial antibiotic treatment consisted of penicillin or amoxi-
cillin monotherapy in 41% of patients, third-generation ceph-
alosporin monotherapy in 22% of patients, and a
combination of penicillin or amoxicillin and a third-generation
cephalosporin in 27% of patients, and different regimens
were used in 10% of patients. Use of aminoglycosides was
reported in 25 episodes and hearing loss at discharge was
found in three of those patients (12%). Aminoglycosides are
associated with ototoxicity and hearing loss; however, there
was no increased risk of hearing loss in patients receiving
aminoglycosides in our study.[16]
Between the ﬁrst and second cohort studies, after the
publication of a clinical trial and meta-analysis,[17,18] adjunc-
tive dexamethasone was introduced as routine treatment in
the Netherlands.[13] In our patient cohorts, the standard
regimen of dexamethasone, 10 mg four times daily, started
with or before the ﬁrst dose of antibiotics, was administered
in 240 of 531 episodes (45%). The proportion of patients
with hearing loss treated with or without standard regimen
dexamethasone was similar (48 of 240 [20%] vs. 68 of 291
[23%]; p = 0.35). The proportion of patients with severe
hearing loss treated with or without standard regimen dexa-
methasone was also similar (20 of 240 [8.3%] vs. 35 of 291
[12%]; p = 0.16).
Discussion
The current study shows that hearing loss frequently compli-
cates pneumococcal meningitis. In our adult population, hear-
ing loss was present in about one in four patients surviving
their disease. Previous studies have reported rates of hearing
loss varying from 7 to 36%. A recent retrospective Danish
study based on a nationwide registration during a 5-year
period (1999–2003) reported a rate of 54%. The majority of
these patients had hearing loss on audiological examination
TABLE 3. Distribution of pneumococcal serotypes in 504 episodes of pneumococcal meningitis according to occurrence of
hearing loss
Serotype
Frequency
(%)
Hearing loss
during clinical
course (%)
Odds ratio
(95% CI) p
Hearing loss
at discharge (%)
Odds ratio
(95% CI) p
14a 38 (8) 8 (30) 0.28 (0.09–0.80) 0.007 6 (16) 0.52 (0.15–1.70) 0.23
19Fa 28 (6) 10 (36) 0.58 (0.20–1.66) 0.26 8 (29) 1.11 (0.35–3.51) 0.85
22F 23 (5) 7 (30) 0.46 (0.14–1.46) 0.14 5 (22) 0.77 (0.20–2.83) 0.66
23Fa 39 (8) 10 (26) 0.36 (0.13–0.98) 0.025 4 (10) 0.32 (0.08–1.19) 0.05
3 49 (10) 24 (49) 1.00 (reference) – 13 (27) 1.00 (reference) –
4a 22 (4) 9 (41) 0.72 (0.23–2.24) 0.53 6 (27) 1.04 (0.29–3.67) 0.94
6Ba 33 (7) 12 (36) 0.60 (0.22–1.61) 0.26 8 (24) 0.89 (0.28–2.74) 0.82
7F 48 (10) 18 (38) 0.63 (0.26–1.52) 0.25 9 (19) 0.64 (0.22–1.85) 0.84
8 31 (6) 12 (39) 0.66 (0.24–1.81) 0.37 8 (26) 0.96 (0.31–3.00) 0.94
9Va 27 (5) 11 (41) 0.72 (0.25–0.52) 0.49 8 (30) 1.17 (0.36–3.72) 0.77
Other serotypes 166 (33) 58 (35) – – 38 (22) – –
Total 504 (100) 179 (36) – – 113 (22) – –
aIncluded in seven valent pneumococcal conjugate vaccine.
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only, without complaints. Our study was performed nation-
wide and, therefore, we were able to study a representative
sample of adults surviving pneumococcal meningitis. Our
prospective approach allowed us to collect comprehensive
data on signs and symptoms, clinical course and outcome.
We identiﬁed otitis as the main risk factor for hearing loss
(OR, 2.58; CI, 1.66–4.02; p < 0.001). This is consistent with
ﬁndings of a previous prospective cohort study that reported
a similar rate of hearing loss among patients with pneumo-
coccal meningitis and otitis (33%).[7] Other studies have
found a relation between markers of CSF inﬂammation and
hearing loss.[4] Our ﬁnding that hearing loss is related to
otitis, but not to disease severity or levels of CSF inﬂamma-
tion, suggests a role for otitis and resulting perilympathic
inﬂammation in the pathogenesis of meningitis-associated
hearing loss, consistent with the aggravated high-frequency
loss in our patients. Research in animals and patients with
bacterial meningitis showed that the main site of the lesion
in meningitis-associated hearing is the cochlea.[5] Predomi-
nant morphological correlates of acute meningitis-associated
hearing loss are damage to the blood-labyrinth barrier, hair
cells and spiral ganglion.[5] However, the route of entry of
bacteria into the cochlea has been subject to debate. Bacte-
ria can reach the cochlea via the bloodstream, the vestibulo-
cochlear nerve, or through the perilymphatic duct. Klein
et al. [5] concluded that the most probable route of infection
is spread of bacteria from the subarachnoid space through
the perilymphatic duct to the perilymphatic space of the
cochlea. However, in otitis media toxic substances (bacterial
products and inﬂammatory mediators) may pass from the
middle ear passage through the round window membrane,
causing perilymphatic inﬂammation, starting within the cochl-
ear basal turn.[19] This localization is consistent with the
prevalence of sensorineural hearing loss at higher frequen-
cies, as found in patients with post-meningitis hearing loss.[5]
Subsequently, these toxic substances may cause permanent
cochlear damage, resulting in hearing loss.[19] The associa-
tion of hearing loss with otitis instead of severity of CSF
inﬂammation would further be supported if the side of otitis
corresponded with the side of hearing loss. The side of oti-
tis, mastoiditis and hearing loss was not systematically regis-
tered in our study, which is a limitation of our results and
leaves room for both versions of the pathophysiology of
hearing loss in pneumococcal meningitis.
Adjunctive dexamethasone therapy was not associated
with a lower risk of hearing loss among survivors of pneu-
mococcal meningitis, although a trend was found for reduced
risk of disabling hearing loss in patients receiving dexametha-
sone. Adjunctive anti-inﬂammatory therapies have been
investigated, with the aim of decreasing rates of post-menin-
gitis hearing loss. Systemic adjunctive steroid treatment
reduced long-term hearing loss in experimental pneumococ-
cal meningitis.[20] Clinical trials and recent meta-analyses
have shown that adjunctive dexamethasone therapy prevents
hearing loss in patients with bacterial meningitis.[21,22] We
recently showed that dexamethasone therapy has been
implemented on a large scale as adjunctive treatment of
adults with pneumococcal meningitis in the Netherlands.[13]
The prognosis of pneumococcal meningitis on a national level
has substantially improved after the introduction of adjunc-
tive dexamethasone therapy.[13] However, as dexametha-
sone improves outcome and reduces mortality, a larger
proportion of patients survive and are at risk of developing
hearing loss. Other adjunctive therapies to prevent hearing
loss (i.e. antioxidant therapy and neurotrophin-3) have been
investigated in animal models and may present promising
future treatment options.[23,24]
Our study has several limitations. As audiological examina-
tion was performed at the discretion of the treating physi-
cian, only 16% of patients received audiological examination.
We extended the deﬁnition of hearing loss to describe all
patients with clinical hearing loss on discharge, even though
bedside assessment of hearing loss is of limited value.[4] The
limited availability of audiological examinations hinders the
interpretation of our results, but reﬂects clinical practice.
Furthermore, in patients with poor clinical outcome, hearing
loss may be masked by clinical condition (e.g. decreased level
of consciousness). Therefore these patients may have been
missed. Finally, treatment data for otitis (mastoidectomy)
were not reported, which is a possible confounder for hear-
ing loss on discharge. However, this does not affect the iden-
tiﬁed association between otitis and hearing loss as a
possible treatment effect is included in this analysis.
Our reference pneumococcal serotype, serotype 3, was
associated with the highest risk of hearing loss. Serotype 23F
was associated with a signiﬁcantly lower risk of hearing loss,
as compared with the serotype 3. The Danish study showed
less hearing loss in patients infected with serotype 6B, but
also found the highest risk in patients infected with serotype
3.[4] A systematic review and meta-analysis of serotype-spe-
ciﬁc disease outcomes for patients with pneumonia and men-
ingitis showed that the relative risk of death in patients
infected with serotype 3 was increased.[25] Experimental
animal studies are needed to further elucidate the role of dif-
ferent pneumococcal serotypes in the risk of meningitis-asso-
ciated hearing loss.
The high incidence of hearing loss in patients with pneu-
mococcal meningitis warrants consultation of an otolaryngol-
ogist in patients with suspected hearing loss.[1] Otitis on
presentation is common in pneumococcal meningitis and may
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require invasive treatment to remove the focus of infection.
Hearing loss may not be clinically evident in patients (e.g.
those with an altered state of consciousness or patients
requiring mechanical ventilation). The threshold for perfom-
ing audiometric evaluation should therefore be low. In
patients with hearing loss due to pneumococcal meningitis,
obliteration of the cochlear lumen may occur in the weeks
after the hearing loss developed. This will further diminish
sensorineural hearing and adversely affects options for
improving hearing, such as cochlear implantation, even in
patients with initial mild hearing loss.[26,27] In these cases,
cochlear implantation before obliteration has occurred may
prevent a permanent disabling hearing impairment.[28,29]
Therefore, otolaryngological evaluation in these patients
should be performed in the acute phase of disease.
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